Literature DB >> 21331463

Lymphedema and breast cancer: a review of the literature.

Michael Stamatakos1, Stamatakos Michael, Charikleia Stefanaki, Stefanaki Charikleia, Konstantinos Kontzoglou, Kontzoglou Konstantinos.   

Abstract

Breast cancer continues to be the most common malignancy among women in the United States. Despite its high incidence, early detection and modern treatment have made long-term survival more common. One of the most important sequelae of the treatment of breast cancer is the development of lymphedema. There are many issues for women to deal with after treatment for breast cancer. Focusing on the quality of life after breast cancer means dealing with issues such as an altered body image, changes in relationships with partner and children, living with any ongoing side effects, and the fear of tumor recurrence. The objective of this paper is to elucidate these issues concerning lymphedema.

Entities:  

Mesh:

Year:  2011        PMID: 21331463     DOI: 10.1007/s12282-010-0246-1

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  17 in total

1.  Quantitative and morphologic change associated with breast cancer-related lymphedema. Comparison of 3.0T MRI to external measures.

Authors:  Gregory C Gardner; Joshua P Nickerson; Richard Watts; Lee Nelson; Kim L Dittus; Patricia J O'Brien
Journal:  Lymphat Res Biol       Date:  2014-03-21       Impact factor: 2.589

Review 2.  Symptom management in metastatic breast cancer.

Authors:  William Irvin; Hyman B Muss; Deborah K Mayer
Journal:  Oncologist       Date:  2011-08-31

Review 3.  Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.

Authors:  Balazs I Bodai; Phillip Tuso
Journal:  Perm J       Date:  2015

4.  The results of the intensive phase of complete decongestive therapy and the determination of predictive factors for response to treatment in patients with breast cancer related-lymphedema.

Authors:  Dilek Keskin; Meltem Dalyan; Sibel Ünsal-Delialioğlu; Ülkü Düzlü-Öztürk
Journal:  Cancer Rep (Hoboken)       Date:  2020-01-03

5.  Lymphatic mapping and preoperative imaging in the management of post-mastectomy lymphoedema.

Authors:  Muhammed Chowdhry; Warren Matthew Rozen; Matthew Griffiths
Journal:  Gland Surg       Date:  2016-04

6.  Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome.

Authors:  Dana M Brantley-Sieders; Aixiang Jiang; Krishna Sarma; Akosua Badu-Nkansah; Debra L Walter; Yu Shyr; Jin Chen
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

7.  Lymphatic abnormalities in the normal contralateral arms of subjects with breast cancer-related lymphedema as assessed by near-infrared fluorescent imaging.

Authors:  Melissa B Aldrich; Renie Guilliod; Caroline E Fife; Erik A Maus; Latisha Smith; John C Rasmussen; Eva M Sevick-Muraca
Journal:  Biomed Opt Express       Date:  2012-05-03       Impact factor: 3.732

8.  Evaluation of the metastatic status of lymph nodes identified using axillary reverse mapping in breast cancer patients.

Authors:  Katsumi Ikeda; Yoshinari Ogawa; Hisateru Komatsu; Yoshihiro Mori; Akira Ishikawa; Takayoshi Nakajima; Gou Oohira; Shinya Tokunaga; Hiroko Fukushima; Takeshi Inoue
Journal:  World J Surg Oncol       Date:  2012-11-01       Impact factor: 2.754

9.  Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery.

Authors:  Christine Miaskowski; Marylin Dodd; Steven M Paul; Claudia West; Deborah Hamolsky; Gary Abrams; Bruce A Cooper; Charles Elboim; John Neuhaus; Brian L Schmidt; Betty Smoot; Bradley E Aouizerat
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

10.  Prospective study evaluating oncological safety of axillary reverse mapping.

Authors:  Eduardo Schunemann; Maíra Teixeira Dória; Janiceli Blanca Carlotto Hablich Silvestre; Plínio Gasperin; Teresa Cristina Santos Cavalcanti; Vinicius Milani Budel
Journal:  Ann Surg Oncol       Date:  2014-03-06       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.